Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7249 and SHR-1918 in Severe Hypertriglyceridemia
NCT07308392Phase 2Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7249, SHR-1918 in hypertriglyceridemia, sponsored by Fujian Shengdi Pharmaceuticals. Started Feb 2026; status: active, not recruiting.
02
Drugs
HRS-7249SHR-1918
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07308392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308392.